- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Glen Stettin on Strategies for Managing High-Cost Treatments
Glen D. Stettin, MD, senior vice president of clinical, research, and new solutions at Express Scripts, discusses what strategies for managing high-cost treatments aren't working and how they could be improved.
Glen D. Stettin, MD, senior vice president of clinical, research, and new solutions at Express Scripts, discusses what strategies for managing high-cost treatments aren't working and how they could be improved.
Transcript (slightly modified)
What current strategies for managing high-cost treatments are not working or could use some improvement?
The strategies that are not working are just relying on guidelines about how medications should be used and expecting that they're going to be followed. There is lots with regards to evidence-based medicine that if fully employed there would be situations where people would be using medication differently, they might choose a different medication, they might choose to forgo to use a medication, to use it at a different dose that would drive a more effective and cost-effective outcome.
How about with specialty drugs?
I think that the challenge with specialty drugs is that given so many of them are just so expensive, there's much less margin of error that the slightest deviation from the best practice guideline has significant implications for cost.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
